• Dasatinib Monohydrate in CML: Translational Insights & Assay

  2026-05-31

  Explore the advanced use of Dasatinib Monohydrate (BMS-354825) in chronic myeloid leukemia research. This article delivers actionable protocol guidance, unique assay insights, and a deep dive into the translational impact of recent findings on neutrophil extracellular trap modulation.

• Palomid 529 (P529): Next-Gen PI3K/Akt/mTOR Inhibition for Tr

  2026-05-30

  Explore the advanced applications of Palomid 529 (P529) in targeting the PI3K/Akt/mTOR pathway for cancer research. This article provides a deep dive into mechanistic insights, translational relevance, and the latest findings on metastasis and therapy resistance.

• Grazoprevir Hydrate: Molecular Precision in HCV Inhibition

  2026-05-29

  Explore the molecular pharmacology of Grazoprevir hydrate as a direct-acting HCV NS3/4A protease inhibitor. This article offers unique insights into its mechanism, pharmacokinetics, and practical assay selection—differentiating it from previous clinical and workflow-focused reviews.

• SNAI1–PIK3R2/p-EphA2 Axis Drives EMT and Stemness in Thymic

  2026-05-29

  This study identifies SNAI1 as a pivotal driver of epithelial-mesenchymal transition (EMT) and maintenance of cancer stem cell-like properties in thymic epithelial tumors (TETs), orchestrated through the PIK3R2/p-EphA2 signaling axis. The multi-omics approach not only elucidates mechanistic underpinnings but also uncovers potential therapeutic targets for these rare malignancies.

• BRD4 Inhibition Enhances Erastin-Induced Ferroptosis via ROS

  2026-05-28

  This study demonstrates that BRD4 inhibition using BET bromodomain inhibitors like (+)-JQ1 amplifies erastin-induced ferroptosis across diverse cell lines by promoting ROS accumulation and downregulating FSP1. These findings clarify the mechanistic interplay between BRD4, ROS, and FSP1 in regulating ferroptotic cell death, highlighting new avenues for combination strategies in cancer therapy.

• Lipo3K Transfection Reagent: Mechanistic Insights & Experime

  2026-05-28

  Explore the advanced mechanism and unique assay advantages of Lipo3K Transfection Reagent. This article reveals how its dual-component design and low cytotoxicity optimize transfection for challenging cell systems.

• (S)-(+)-Dimethindene maleate: Technical Guide for M2 Antagon

  2026-05-27

  (S)-(+)-Dimethindene maleate provides selective inhibition of M2 muscarinic and H1 histamine receptors, enabling precise interrogation of autonomic, cardiovascular, and respiratory pathways in preclinical research. It is not suitable for diagnostic or medical use, and its solution stability requires careful handling for reproducible results.

• β-Adrenergic Blockade and Hematopoietic Regeneration Post-HC

  2026-05-27

  This study reveals that nonselective β-adrenergic receptor blockers, such as carvedilol, impair hematopoietic regeneration after hematopoietic cell transplantation (HCT) in mice and humans, while β1-selective inhibition with metoprolol does not. The findings clarify the selective roles of adrenergic receptor subtypes in bone marrow recovery and inform clinical strategies for managing β-blocker therapy in HCT patients.

• Anlotinib Hydrochloride: Redefining Multi-Target Angiogenesi

  2026-05-26

  This thought-leadership article dissects the mechanistic power and translational advantages of Anlotinib hydrochloride as a multi-target tyrosine kinase inhibitor. Drawing from seminal preclinical evidence and contemporary assay intelligence, it guides cancer researchers through experimental best practices, competitive positioning, and the practical realities of endothelial cell migration inhibition and capillary tube formation assays. Building on the robust literature and comparative analysis, this discussion advances beyond standard product descriptions to deliver actionable, evidence-based strategies for translational oncology.

• CUDC-907: Technical Guidance for Dual PI3K and HDAC Inhibiti

  2026-05-26

  CUDC-907 is a dual PI3K and HDAC inhibitor for in vitro research, enabling targeted studies of cell signaling, cell cycle arrest, and apoptosis in cancer models. It is intended for controlled laboratory workflows and should not be used for diagnostic or therapeutic purposes.

• Tin Mesoporphyrin IX (chloride): Precision Inhibition and HO

  2026-05-25

  Explore Tin Mesoporphyrin IX (chloride) as a precision tool for dissecting heme oxygenase activity in metabolic and viral disease research. This article uniquely bridges mechanistic inhibition, advanced assay design, and emerging insights from HO-1 modulation.

• Grazoprevir/Elbasvir for HCV: Advances in Direct-Acting Anti

  2026-05-25

  The reference review details the clinical impact of the grazoprevir/elbasvir fixed-dose combination, highlighting its efficacy and tolerability in chronic hepatitis C virus (HCV) infection. The innovation lies in interferon-free regimens that achieve high sustained virologic response (SVR) rates, including in challenging populations such as those with HIV/HCV coinfection or chronic kidney disease.

• BRD4 Inhibition Potentiates Ferroptosis via ROS and FSP1 Mod

  2026-05-24

  The referenced study demonstrates that BRD4 inhibitors, including I-BET-762, markedly enhance erastin-induced ferroptosis across diverse cell lines by promoting ROS accumulation and suppressing FSP1 expression. This work clarifies the mechanistic role of BRD4 in ferroptosis regulation and suggests new combinatorial strategies for cancer therapy.

• Scalable iMSC-EV Biomanufacturing for Pulmonary Fibrosis The

  2026-05-23

  Gong et al. present a robust, scalable platform for producing extracellular vesicles (EVs) from induced mesenchymal stem cells (iMSCs) derived from extended pluripotent stem cells (EPSCs), addressing key barriers in regenerative EV therapies. This study demonstrates that iMSC-EVs match primary MSC-EVs in therapeutic efficacy, offering a practical path toward standardized, GMP-compliant cell-free therapies for fibrotic disease.

• BMS-345541: Redefining NF-κB Modulation in Translational Res

  2026-05-22

  Explore how BMS-345541 (free base) enables precise IKK-1/IKK-2 inhibition, bridging mechanistic insights with translational strategy for inflammation, cancer, and vascular biology.

14678 records 3/979 page Previous Next 12345 下5页 Last page